

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

HOUSE MEMORIAL 58

57TH LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2025

INTRODUCED BY

Dayan Hochman-Vigil

A MEMORIAL

REQUESTING THE DEPARTMENT OF HEALTH TO STUDY PSILOCYBIN-BASED
MEDICATION TREATMENT.

WHEREAS, psilocybin, a naturally occurring psychedelic
compound found in certain mushrooms, has gained recognition for
its potential therapeutic applications, including treatment for
mental health conditions such as depression, anxiety and
posttraumatic stress disorder; and

WHEREAS, the use of psilocybin-based treatments has become
a topic of increasing interest in the medical and scientific
communities, with several jurisdictions across the United
States and globally exploring regulatory frameworks for the use
of psilocybin-based treatments in clinical settings; and

WHEREAS, New Mexico has recognized the importance of
advancing evidence-based health care solutions and ensuring the

underscoring material = new
~~[bracketed material] = delete~~

underscored material = new
~~[bracketed material] = delete~~

1 safety, efficacy and accessibility of new treatment modalities
2 for its residents; and

3 WHEREAS, the department of health plays a central role in
4 regulating health care practices and safeguarding public health
5 within the state; and

6 WHEREAS, New Mexico would benefit from standardized
7 guidelines that ensure appropriate training for medical
8 professionals and robust testing protocols for psilocybin-based
9 treatments;

10 NOW, THEREFORE, BE IT RESOLVED BY THE HOUSE OF
11 REPRESENTATIVES OF THE STATE OF NEW MEXICO that the department
12 of health be requested to study the following:

13 A. the standardization of training requirements and
14 modalities for the use of psilocybin-based medication treatment
15 by examining the current landscape of psilocybin-based
16 medication treatments;

17 B. the establishment of clear testing protocols to
18 ensure the consistency, accuracy and safety of psilocybin
19 products;

20 C. the methods for determining psilocybin content,
21 variability in potency and quality control measures that
22 protect both patients and providers;

23 D. the considerations of both initial and ongoing
24 training requirements, ensuring that the training modalities
25 support safe, effective and ethical use of psilocybin as a

.231353.2

1 therapeutic treatment;

2 E. the review of existing legal and regulatory
3 barriers to psilocybin-based medication treatment, including
4 state and federal restrictions, and recommendations for policy
5 adjustments that may facilitate safe and controlled access;

6 F. the examination of potential frameworks for
7 licensing, administration and oversight, including whether
8 psilocybin-based treatment should be limited to medical
9 professionals, offered in supervised clinical settings or made
10 available through licensed facilitators;

11 G. the evaluation of public health and safety
12 concerns, including considerations for proper screening of
13 patients, contraindications and integration with existing
14 mental health care services;

15 H. the assessment of economic and social equity
16 impacts, including strategies to ensure affordable and
17 equitable access to psilocybin-based treatments for underserved
18 populations, as well as opportunities for community
19 participation in the development of a regulatory framework;

20 I. the engagement of medical and scientific
21 experts, including representatives from universities, research
22 institutions and clinical trial programs, to provide guidance
23 on evidence-based best practices and safety standards;

24 J. the solicitation of input from stakeholders,
25 including health care professionals, indigenous and traditional

.231353.2

underscoring material = new
~~[bracketed material] = delete~~

1 medicine practitioners, mental health advocacy organizations
2 and members of the public, to inform policy recommendations;

3 K. the identification of potential funding sources
4 for future research and implementation efforts, including
5 federal grants, private research partnerships and state
6 appropriations; and

7 L. the establishment of a time line for
8 implementing any recommended regulatory or legislative changes
9 following the completion of the study, ensuring that findings
10 are used to inform future policymaking efforts; and

11 BE IT FURTHER RESOLVED that the department of health be
12 requested to submit a comprehensive report detailing the
13 department's findings, recommended policy changes and a
14 proposed framework for psilocybin-based medication treatment,
15 including potential pilot programs, licensing structures and
16 public health safeguards; and

17 BE IT FURTHER RESOLVED that a copy of this memorial be
18 transmitted to the secretary of health.

19 - 4 -
20
21
22
23
24
25